Hair Repigmentation Associated With the Use of Brentuximab

This study found that nearly 40% of Hodgkin’s Lymphoma patients who received Brentuximab Vedotin with AVD chemotherapy experienced persistent alopecia more than two years after treatment, leading to significant psychosocial consequences such as reduced self-confidence and emotional distress.

This report describes a patient experiencing hair repigmentation linked to adalimumab therapy, a TNF inhibitor, a phenomenon not previously associated with this class of drugs.

This study describes changes in scalp hair color, including rare instances of repigmentation, following volumetric modulated arc therapy for skin cancer; this potential side effect may warrant discussion during informed consent.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

In this case report, researchers observed hair repigmentation in a man with metastatic renal cell carcinoma during treatment with axitinib, marking the first documented instance of this effect with axitinib without the use of hair dyes or other medications.